Loading...
XNASEDSA
Market cap35mUSD
Dec 23, Last price  
1.73USD
1D
-0.21%
1Q
-60.41%
Jan 2017
-99.71%
IPO
-99.71%
Name

Edesa Biotech Inc

Chart & Performance

D1W1MN
XNAS:EDSA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
37.30%
Rev. gr., 5y
-12.98%
Revenues
0k
00854,837697,187286,054545,469372,132758,6891,271,689228,287211,849410,870328,8010000
Net income
-6m
0-73,917-589,971-7,086,123-5,196,696-14,886,513-8,439,523-2,843,029-5,026,080-5,030,648-5,038,949-2,721,330-6,364,230-13,343,150-17,548,9240-6,170,045
CFO
-5m
L-26.31%
-37,667-732,227-2,616,542-3,947,814-2,924,965-4,266,707-4,412,395-4,505,629-4,699,649-4,615,505-4,845,787-4,986,340-13,664,931-12,279,302-6,636,483-4,890,205
Earnings
Feb 07, 2025

Profile

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
URL
https://www.edesabiotech.com/
IPO date
Aug 25, 2008
Employees
16
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
Cost of revenue
7,015
9,223
18,489
Unusual Expense (Income)
NOPBT
(7,015)
(9,223)
(18,489)
NOPBT Margin
Operating Taxes
800
800
800
Tax Rate
NOPAT
(7,016)
(9,224)
(18,490)
Net income
(6,170)
 
(17,549)
31.52%
Dividends
Dividend yield
Proceeds from repurchase of equity
729
4,345
11,958
BB yield
Debt
Debt current
20
75
19
Long-term debt
20
114
19
Deferred revenue
Other long-term liabilities
44
Net debt
(998)
(5,172)
(7,053)
Cash flow
Cash from operating activities
(4,890)
(6,636)
(12,279)
CAPEX
(6)
Cash from investing activities
(6)
Cash from financing activities
592
4,830
11,630
FCF
(6,796)
(9,292)
(15,538)
Balance
Cash
1,037
5,361
7,091
Long term investments
Excess cash
1,037
5,361
7,091
Stockholders' equity
(11,596)
(5,990)
(1,785)
Invested Capital
13,597
13,134
11,239
ROIC
ROCE
EV
Common stock shares outstanding
3,197
2,859
2,096
Price
Market cap
EV
EBITDA
(6,829)
(9,039)
(18,371)
EV/EBITDA
Interest
823
Interest/NOPBT